27.90
-0.15 (-0.53%)
| Previous Close | 28.05 |
| Open | 28.60 |
| Volume | 35,650 |
| Avg. Volume (3M) | 336,081 |
| Market Cap | 14,762,475,520 |
| Price / Earnings (TTM) | 14.16 |
| Price / Earnings (Forward) | 14.66 |
| Price / Sales | 2.04 |
| Price / Book | 0.960 |
| 52 Weeks Range | |
| Earnings Date | 6 Mar 2025 - 10 Mar 2025 |
| TTM Dividend Yield | 4.37% |
| Profit Margin | 15.66% |
| Operating Margin (TTM) | 16.35% |
| Diluted EPS (TTM) | 1.98 |
| Quarterly Revenue Growth (YOY) | 0.20% |
| Quarterly Earnings Growth (YOY) | -13.10% |
| Total Debt/Equity (MRQ) | 7.50% |
| Current Ratio (MRQ) | 4.30 |
| Operating Cash Flow (TTM) | 673.52 M |
| Levered Free Cash Flow (TTM) | 149.73 M |
| Return on Assets (TTM) | 3.53% |
| Return on Equity (TTM) | 6.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | HAOHAI BIOTEC | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HAOHAI BIOTEC | 15 B | 4.37% | 14.16 | 0.960 |
| 3SBIO | 15 B | 3.86% | 8.67 | 0.910 |
| KEYMED BIO-B | 8 B | - | - | 2.92 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
| BEIGENE | 195 B | - | - | 6.93 |
|
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to single operating segment which is the manufacture and sale of biologicals, medical hyaluronate and intraocular lens, research and development of biological engineering and pharmaceutical products and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 0.07% |
| % Held by Institutions | 23.34% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |